S. Acholonu

发表

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

E. Shpall, P. Mclaughlin, J. Manning, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.

P. Mclaughlin, N. Ueno, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

P. Mclaughlin, A. Younes, L. Fayad, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center

N. Ueno, B. Andersson, Y. Nieto, 2012, Leukemia & lymphoma.

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results

E. Shpall, A. Younes, Y. Nieto, 2012, Leukemia & lymphoma.

Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.

Wei Wei, R. Champlin, M. Duvic, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term follow‐up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission

R. Champlin, I. Khouri, R. Saliba, 2003, Cancer.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

N. Ueno, D. Couriel, R. Champlin, 2004, Bone Marrow Transplantation.

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia

E. Shpall, U. Popat, M. Qazilbash, 2011, Leukemia & lymphoma.

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, A. Younes, 2005, Bone Marrow Transplantation.

High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma

D. Couriel, R. Champlin, J. Mcmannis, 2006, Leukemia & lymphoma.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience

M. Munsell, N. Ueno, B. Andersson, 2008, Haematologica.

26 Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease (HD)

N. Ueno, B. Andersson, D. Couriel, 2003 .

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

P. Mclaughlin, A. Younes, L. Fayad, 2005 .

Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, L. Fayad, 2005 .